NR4A1 and breast carcinoma: One of the comparisons in BIG 1-98 was the effect of monotherapy with letrozole (an aromatase inhibitor) or tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor–positive breast cancer on the risk of death.